Patients with atopic dermatitis (AD) who achieve completely clear skin with tapinarof (Vtama) cream maintain low disease ...
Patients with atopic dermatitis (AD) who achieve completely clear skin with tapinarof (Vtama) cream maintain low dise ...
Organon has shared positive results from a long-term extension (LTE) study of its Vtama (tapinarof) cream, 1% in atopic ...
Atopic dermatitis disease activity remained mild after patients treated with Vtama cream 1% achieved nearly 80 consecutive ...
The Prime Minister, Justin Trudeau, today issued the following statement on International Women's Day: "Women in Canada have made transformative progress in shaping our country for the better. Today, ...
A break from treatment with Vtama won’t lead to worsening of patients’ atopic dermatitis, finds a new analysis of an ...
9d
MedPage Today on MSNTopical Therapies for PsoriasisOptimizing use of topical agents begins with defining "mild or moderate." Clinical trials in psoriasis employ objective ...
Currently available fixed combination topicals have robust efficacy, and the recently approved cream formulations of tapinarof and roflumilast appear to have efficacy that may be higher than ...
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced new data from two implementation studies showing zero cases of ...
The company recently announced that the FDA had approved VTAMA (tapinarof) cream for the treatment of atopic dermatitis in adults and children two years of age and up. While promoting expansion ...
Opzelura is a treatment for nonsegmental vitiligo in patients 12 and older, making it the first and only cream in the U.S. that helps restore skin color for this condition. It’s also approved to treat ...
JERSEY CITY, N.J., November 05, 2024--The U.S. Food and Drug Administration (FDA) announced the target action date of its review of the sNDA for VTAMA (tapinarof) cream, 1% has changed. Organon & ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results